ANDA 40668, held by Rising. Cyproheptadine Hydrochloride.
As of Nov 16, 2026, ANDA 40668 (Cyproheptadine Hydrochloride), held by Rising, was first approved by FDA on Jun 28, 2006, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema Amelioration of allergic reactions to blood or plasma Cold urticaria Dermatographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 28, 2006 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Cyproheptadine Hydrochloride2MG/5ML · syrup;oral | Cyproheptadine Hydrochloride | Rx |
| Dec 3, 2006 | Supplement 1Labeling | Approved | None posted |
| Jun 28, 2006 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters